[go: up one dir, main page]

WO2005124359A3 - Procede de diagnostic et de traitement du diabete et de l’insulinoresistance - Google Patents

Procede de diagnostic et de traitement du diabete et de l’insulinoresistance Download PDF

Info

Publication number
WO2005124359A3
WO2005124359A3 PCT/US2005/021296 US2005021296W WO2005124359A3 WO 2005124359 A3 WO2005124359 A3 WO 2005124359A3 US 2005021296 W US2005021296 W US 2005021296W WO 2005124359 A3 WO2005124359 A3 WO 2005124359A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diagnosing
insulin resistance
treating diabetes
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/021296
Other languages
English (en)
Other versions
WO2005124359A2 (fr
Inventor
Shonna A Moodie
Brian E Lavan
Thomas A Gustafson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
Metabolex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolex Inc filed Critical Metabolex Inc
Priority to JP2007516736A priority Critical patent/JP2008502909A/ja
Publication of WO2005124359A2 publication Critical patent/WO2005124359A2/fr
Publication of WO2005124359A3 publication Critical patent/WO2005124359A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L’invention concerne des compositions et des procédés de diagnostic et de traitement du diabète et de l’insulinoresistance. En particulier, l’invention concerne des procédés d’identification des modulateurs des polynucléotides ou des polypeptides de l’invention, ainsi que l’utilisation de ces modulateurs pour traiter le diabète. L’invention concerne en outre des procédés de diagnostic du diabète qui consistent à mesurer les taux de polynucléotides ou de polypeptides de l’invention chez le patient.
PCT/US2005/021296 2004-06-15 2005-06-15 Procede de diagnostic et de traitement du diabete et de l’insulinoresistance Ceased WO2005124359A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007516736A JP2008502909A (ja) 2004-06-15 2005-06-15 糖尿病およびインスリン抵抗性の診断および治療の方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58029004P 2004-06-15 2004-06-15
US60/580,290 2004-06-15

Publications (2)

Publication Number Publication Date
WO2005124359A2 WO2005124359A2 (fr) 2005-12-29
WO2005124359A3 true WO2005124359A3 (fr) 2006-02-16

Family

ID=35510374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/021296 Ceased WO2005124359A2 (fr) 2004-06-15 2005-06-15 Procede de diagnostic et de traitement du diabete et de l’insulinoresistance

Country Status (2)

Country Link
JP (1) JP2008502909A (fr)
WO (1) WO2005124359A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11976282B2 (en) 2020-06-23 2024-05-07 Qatar University GATA3 inhibitors for the promotion of subcutaneous fat deposition
EP4562136A1 (fr) * 2022-07-28 2025-06-04 University of Maryland, Baltimore Inhibiteurs de pde11a4 et leurs méthodes d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077949A2 (fr) * 2002-03-14 2003-09-25 Bayer Pharmaceuticals Corporation Procedes relatifs au traitement du diabete par administration d'inhibiteurs de pde11a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077949A2 (fr) * 2002-03-14 2003-09-25 Bayer Pharmaceuticals Corporation Procedes relatifs au traitement du diabete par administration d'inhibiteurs de pde11a

Also Published As

Publication number Publication date
JP2008502909A (ja) 2008-01-31
WO2005124359A2 (fr) 2005-12-29

Similar Documents

Publication Publication Date Title
WO2008030273A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2009038689A3 (fr) Compositions et procédés pour le diagnostic et le traitement du diabète de type 2
WO2008042231A3 (fr) Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
WO2007067341A3 (fr) Compositions et procedes d’augmentation de la sensibilite a l’insuline
IL198922A0 (en) Chemical compounds and uses
WO2008055491A3 (fr) Diagnostic et stratification des risques de diabète sucré par mr-proadm
WO2006044531A3 (fr) Modulation antisens de l'expression de ptp1b
WO2007056457A3 (fr) Procedes, compositions et kits pour le traitement de pathologies
WO2006053043A3 (fr) Methodes de traitement du diabete sucre
WO2008027687A3 (fr) Méthode de traitement d'avc à l'aide d'un agent thrombolytique
WO2007079171A3 (fr) Traitement du lymphome de hodgkin
WO2011002834A3 (fr) Compositions et procédés de diagnostic et de traitement du diabète de type i
WO2009023048A3 (fr) Marqueurs du syndrome métabolique
WO2007079146A8 (fr) Traitement pour un lymphome non hodgkinien
WO2006017171A3 (fr) Methodes de diagnostic et de traitement de l'obesite, du diabete et de l'insulinoresistance
WO2003101284A3 (fr) Procedes de diagnostic et de traitement de diabetes et de l'insulinoresistance
WO2005034737A3 (fr) Diagnostic et traitement de troubles du reticulum endoplasmique
WO2006128041A3 (fr) Compositions et procedes destines a traiter ou a prevenir un neoplasme chimiomoresistant
WO2007117794A3 (fr) Peptides glyqués et procédés d'utilisation
WO2008059041A3 (fr) Complémentation d'un déficit de facteur xi par mutants de facteur v
WO2006007400A9 (fr) Procedes de diagnostic et de traitement de l'obesite, du diabete et de la resistance a l'insuline
WO2003102161A3 (fr) Methodes de diagnostic et de traitement du diabete et de l'insulinoresistance
WO2005124359A3 (fr) Procede de diagnostic et de traitement du diabete et de l’insulinoresistance
WO2006010051A3 (fr) Methodes de diagnostic et de traitement de diabetes et de resistance a l'insuline
WO2007079312A3 (fr) Compositions et procédés de traitement d’affections pathologiques médiées par l'actine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007516736

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase